ABBOTT LABORATORIES(ABT)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
ABBOTT LABORATORIES (ABT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABT at 65.5/100 on a 32-signal composite quality model, placing it at rank #479 of 2,960 stocks — the top 25% of the AI-ranked universe. ABT scores in the top quartile across revenue scale (96.7), balance sheet strength (75.6). Shareholder dilution risk is elevated at 46.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ABBOTT LABORATORIES reports quarterly revenue of $11.2B, net income of $1.1B, an operating margin of 12.0%. Top institutional holders of ABT by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABT trades on the NYSE exchange and files with the SEC under CIK 1800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABBOTT LABORATORIES directly from SEC EDGAR.
AI Quality Score
65.5/100
AI Rank
#479
Revenue
$11.2B
Net Income
$1.1B
Free Cash Flow
$916.0M
Operating Margin
12.0%
ABT key financials by period
ABBOTT LABORATORIES reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$44.3B
$6.5B
18.2%
FY 2024
10-K
$42.0B
$13.4B
16.3%
FY 2023
10-K
$40.1B
$5.7B
16.2%
FY 2022
10-K
$43.7B
$6.9B
19.2%
FY 2021
10-K
$43.1B
$7.1B
19.6%
FY 2020
10-K
$34.6B
$4.5B
15.5%
Institutions holding ABT
Institutional investors reporting a position in ABBOTT LABORATORIES on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-28 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net sales rose 13.0% to $12.6B on the $20.6B Exact Sciences acquisition, but net earnings fell to $928M from $1,779M as deal costs, amortization, and interest expense surged.
Biggest Revenue Drivers
Medical Devices$5,853M+9.0% YoY
High single-digit growth in Medical Devices; +7.9% excluding foreign exchange
Diagnostic Products$3,092M+42.3% YoY
Driven by the Exact Sciences acquisition completed March 23, 2026, reported as Cancer Diagnostics
Biggest Revenue Drivers
Total revenue: $12,593M+13.0% YoY
Medical Devices$5,853M+9.0% YoY
High single-digit growth in Medical Devices; +7.9% excluding foreign exchange
Within Medical Devices
Diabetes Care$2,188M
Continued growth in continuous glucose monitoring systems in the U.S. and internationally
Diagnostic Products$3,092M+42.3% YoY
Driven by the Exact Sciences acquisition completed March 23, 2026, reported as Cancer Diagnostics
Within Diagnostic Products
Cancer Diagnostics$919M
Exact Sciences sales, including Cologuard, Oncotype DX, and Cancerguard, since acquisition
Nutritional Products$2,144M-3.1% YoY
Lower sales volumes across adult nutritional and U.S. pediatric product portfolios
Largest Expense Items
Cost of products sold, excluding amortization$5,325Mvs $4,854M prior year
Unfavorable impact of higher costs, partially offset by favorable business mix and margin improvement initiatives
Selling, general, and administrative$4,025M+30.3% YoY
Addition of Exact Sciences and integration expenses, higher legal reserves, increased selling and marketing spend, unfavorable foreign exchange
Research and development$892M+22.9% YoY
Addition of the Exact Sciences business and continued investment in development programs across multiple businesses
Amortization of intangible assets$658Mvs $420M prior year
Higher intangible amortization related to the Exact Sciences acquisition
Margins: Gross margin was 52.5% in Q2 2026 versus 52.7% a year earlier, reflecting higher Exact Sciences intangible amortization and higher costs, partly offset by favorable mix and margin initiatives.
Watch Items from the Filing
Exact Sciences bought for $20.6B, funded with $20.0B of new debt; long-term debt rose to $29.6B from $9.9B and net interest expense hit $299M versus $50M.
Missouri Court of Appeals affirmed the $495M NEC infant-formula verdict in May 2026; Abbott cannot estimate a loss range and has recorded no reserves.
Rapid and Molecular Diagnostics sales fell to $755M from $815M, down 8.8% for six months excluding FX on weaker respiratory virus season.
IRS Statutory Notices of Deficiency total $417M (2019), $192M (2017-2018), and $443M (2020); a $413M Malaysian assessment was upheld and is under appeal.
Goodwill of $35.2B and net intangibles of $17.2B now equal roughly half of $109.2B total assets; purchase price allocation is preliminary and could change materially.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
